Omzet 2024 * | 76,08 mln. 70,06 mln. | Omzet 2025 * | 68,35 mln. 62,94 mln. | Marktkapitalisatie | 321 mln. 296 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -155 mln. -143 mln. | Nettowinst (verlies) 2025 * | -170 mln. -157 mln. | EV/omzet 2024 * | 2,72 x |
Nettoliquiditeiten 2024 * | 115 mln. 106 mln. | Nettoliquiditeiten 2025 * | 281 mln. 259 mln. | EV/omzet 2025 * | 0,58 x |
K/w-verhouding 2024 * |
-2,17
x | K/w-verhouding 2025 * |
-2,47
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 94,63% |
Recentste transcriptie over Nektar Therapeutics
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Howard Robin
CEO | Chief Executive Officer | 71 | 01-01-07 |
Robert Chess
CHM | Chairman | 66 | 01-12-91 |
Sandra Gardiner
DFI | Director of Finance/CFO | 58 | 17-04-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
R. Greer
BRD | Director/Board Member | 65 | 01-01-10 |
Roy Whitfield
BRD | Director/Board Member | 70 | 01-08-00 |
Robert Chess
CHM | Chairman | 66 | 01-12-91 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+34,35% | 705 mld. | |
+29,39% | 583 mld. | |
-3,49% | 364 mld. | |
+20,15% | 332 mld. | |
+6,19% | 291 mld. | |
+14,11% | 238 mld. | |
-3,03% | 210 mld. | |
+10,02% | 209 mld. | |
+9,21% | 169 mld. |